---
title: "Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283323749.md"
description: "Sihuan Pharmaceutical Holdings Group announced promising early results from the Phase 1b FORTRESS trial of NG-350A for locally advanced rectal cancer. The trial showed a 50% clinical response rate in the first 10 patients, significantly higher than the typical 25% with standard treatment. No serious adverse events were reported, indicating a favorable safety profile. These findings may enhance treatment outcomes for high-risk patients and strengthen Sihuan's position in colorectal cancer therapies as they pursue further clinical trials in mainland China."
datetime: "2026-04-20T09:09:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283323749.md)
  - [en](https://longbridge.com/en/news/283323749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283323749.md)
---

# Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.

Sihuan Pharmaceutical announced that preliminary data from the Phase 1b FORTRESS trial of NG-350A in patients with mismatch repair-proficient locally advanced rectal cancer were presented at the 2026 AACR meeting. NG-350A, combined with standard chemoradiotherapy, achieved a 50% composite clinical response rate in the first 10 patients over 12 weeks, roughly double the typical 25% rate seen with chemoradiotherapy alone.

The early results showed no serious adverse events or new safety signals linked to NG-350A, underscoring a favorable safety and tolerability profile in this setting. The findings suggest NG-350A could enhance outcomes for high-risk rectal cancer patients and strengthen Sihuan’s and Xuanzhu’s position in advanced colorectal cancer treatment as they push forward with clinical trial applications in mainland China.

**More about Sihuan Pharmaceutical Holdings Group**

Sihuan Pharmaceutical Holdings Group is a Hong Kong-listed pharmaceutical company with a focus on innovative oncology therapies through its subsidiary Xuanzhu Biopharmaceutical. Xuanzhu holds exclusive Greater China rights to NG-350A, an oncolytic immunotherapy sourced from U.S.-based Akamis Bio, and is advancing its clinical development and commercialization in the region.

**YTD Price Performance:** 17.89%

**Average Trading Volume:** 35,639,862

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$13.53B

Learn more about 0460 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [00460.HK](https://longbridge.com/en/quote/00460.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)

## Related News & Research

- [Instalco unit Vallacom signs Stångåstaden data network framework deal](https://longbridge.com/en/news/287012046.md)
- [JFAB Consulting Elevates Brand with New Identity and Digital Experience](https://longbridge.com/en/news/286924471.md)
- [Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances](https://longbridge.com/en/news/286835606.md)
- [China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen](https://longbridge.com/en/news/286577625.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)